Mounjaro maintains top spot among GLP-1 drugs

Ozempic once dominated the headlines, but GLP-1 competitor Mounjaro is winning over customers.

GLP-1 drugs, used for treating diabetes and aiding in weight loss, are relatively new on the market yet have surged in popularity over the last year. They're becoming so popular that J.P. Morgan estimates that 30 million people in the US may be using a GLP-1 drug by 2030. This statistic presents a significant potential for early drug creator Novo Nordisk (Ozempic, Wegovy), and perhaps an even bigger one for Eli Lilly (Mounjaro, Zepbound).

HundredX data indicates Eli Lilly is in a position to win over Novo Nordisk as Mounjaro's Usage Intent widens against the competition. Ozempic may have name recognition, but customers feel more positively about Mounjaro's effectiveness and lifestyle impact, even if they aren't excited about its high price.

Examining 1,500 pieces of customer feedback across Mounjaro, Ozempic, and Wegovy, we find:

GLP-1 users increasingly say they plan to use Mounjaro more, and Ozempic less. Mounjaro’s Usage Intent is up 19% since July, Wegovy’s is up 3%, and Ozempic has stayed within a tight range.
Customers feel Mounjaro is more effective than competing drugs, but it’s harder to get. Mounjaro outperforms other GLP-1 drugs in effectiveness, lifestyle impact, and side effects. However, customers dislike its cost and availably more than competitors.

Slide title

Write your caption here

Button
Slide title

Over the past few months, patients have increasingly said they plan to use Mounjaro more, while saying they plan to use Ozempic less. It appears Wegovy is starting to recover after significantly falling in Usage Intent in December.

Button
Slide title

Mounjaro outperforms on factors related to effectiveness, but lags on availability and cost.

Button
Slide title

Compared to the average HundredX respondent, GLP-1 users are more likely to spend less on fast-food and use the gym less.

Button
Slide title

Write your caption here

Button

Please contact our team for a deeper look at HundredX's data on prescription medication, which includes more than 130,000 pieces of customer feedback across 206 medications.

All metrics presented, including Net Usage (Usage Intent) and Net Positive Percent / Favorability, are presented on a trailing three-month basis unless otherwise noted.
Usage Intent represents the percentage of customers who expect to use a medication more over the next 12 months, minus those who intend to use it less. We find businesses that see Usage Intent trends gain versus the industry or peers have often seen revenue growth rates, margins, and/or market share also improve versus peers.
HundredX measures Net Favorability towards a driver of customer satisfaction as Net Positive Percent (NPP), which is the percentage of customers who view a factor as a positive (reason they liked the products, people, or experiences) minus the percentage who see the same factor as a negative.

Strategy Made Smarter

HundredX works with a variety of companies and their investors to answer some of the most important strategy questions in business:

Where are customers "migrating"?
What are they saying they will use more of in the next 12 months?
What are the key drivers of their purchase decisions and financial outcomes?

Current clients see immediate benefits across multiple areas including strategy, finance, operations, pricing, investing, and marketing.

Our insights enable business leaders to define and identify specific drivers and decisions enabling them to grow their market share.

Please contact our team to learn more about which businesses across 80+ industries are best positioned with customers and the decisions you can make to grow your brand’s market share.

####

HundredX is a mission-based data and insights provider. HundredX does not make investment recommendations. However, we believe in the wisdom of the crowd to inform the outlook for businesses and industries. For more info on specific drivers of customer satisfaction, other companies within 75+ other industries we cover, or if you'd like to learn more about using Data for Good, please reach out: https://hundredx.com/contact.

< Older Post

Newer Post >

Share This Article

Starbucks shows weakness as consumers feel worse about taste

06 May, 2024

Sure, lattes, mochaccinos, and cappuccinos are pricey, but they taste delicious. For many consumers, the great taste of coffee shop coffee made it worth the cost. But customers at Starbucks aren't so sure the tradeoff is worth it anymore. Examining more than 420,000 pieces of feedback across the Quick, Fast, Casual (QFC) industry, including over 21,000 on Starbucks, we find: Starbuck's Purchase Intent 1,2 is down 3% over the past six months, with most of that dip occurring over the past few months. By contrast, Dunkin' Donuts has remained within a tight range over the past six months, as did an average of other, smaller coffee chains. Customers increasingly see less value in Starbucks. Starbuck's Value perception 3 fell 5% over the past six months, compared to just 1% for Dunkin' Donuts. However, it also fell 5% for the average of the smaller coffee chains. Coffee drinkers feel significantly unhappier about Starbuck's quality and taste. Starbuck's Taste perception fell 4% over the past six months, while rising 1% for competitors. Likewise, its Quality perception dipped 3% over the same time period (and 8% over the year). Ultimately, Starbuck's perceived drop in taste is leading inflation-weary consumers to say they plan to spend less at the coffee chain, as the value just isn't as good.